|
|
|
|
|
|
|
M T W Thu F |
|
16 July, 2026 |
|
|
|
|
|
|
|
|
|
|
At the Alzheimer’s Association International Conference in London, Ryan Cross spoke with Betty Tijms, a researcher who discovered five distinct subtypes of Alzheimer's as the field seems stuck on amyloid and tau pathology. Read their conversation here. |
|
|
|
Alex Hoffman |
Copy Chief and News Editor, Endpoints News
|
|
|
|
 |
|
Betty Tijms, the head of science at Alzheimer Center Amsterdam |
|
|
|
by Ryan Cross
|
LONDON— For more than a century, scientists studying Alzheimer’s have largely focused their efforts on two proteins — amyloid and tau — that clearly... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Sanofi and Arbutus are each going to court over alleged violations of their respective mRNA patents, adding to a growing list of companies making similar... | |
|
|
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Vogenx and Orakl Oncology. 🇨🇳 Kelun touts China data for sac-TMT: Kelun-Biotech announced on Tuesday that its Merck-partnered antibody-drug conjugate sacituzumab tirumotecan succeeded... | |
|
|
|
|
|
|
by Reynald Castaneda
|
Eli Lilly said on Thursday it will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, in a move that further spotlights big pharma’s increasing... | |
|
|
|
|
|
|
|
